BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11378632)

  • 1. Choice of lipid-regulating drugs.
    Med Lett Drugs Ther; 2001 May; 43(1105):43-8. PubMed ID: 11378632
    [No Abstract]   [Full Text] [Related]  

  • 2. Drugs for lipids.
    Treat Guidel Med Lett; 2005 Mar; 3(31):15-22. PubMed ID: 15726011
    [No Abstract]   [Full Text] [Related]  

  • 3. LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
    Phillips W; Schaefer S
    Prev Cardiol; 2010; 13(2):69-71. PubMed ID: 20377808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    März W
    MMW Fortschr Med; 2005 Apr; 147(14):14. PubMed ID: 15887675
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of dyslipoproteinemia risk factor. Lipid therapy must become multidimensional].
    MMW Fortschr Med; 2008 Jun; 150(26-27):52-3. PubMed ID: 18681233
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidaemia in diabetes.
    Patel J
    Clin Evid; 2006 Jun; (15):555-75. PubMed ID: 16973026
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current drug treatments for lipid management.
    Stone NJ
    Manag Care; 2002 Sep; 11(9 Suppl):4-9. PubMed ID: 12369341
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myopathy caused by a combination rosuvastatin and fenofibrate.
    Dedhia V; Munsi SC
    J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug treatment of hyperlipidemia].
    Zazgornik J; Koch S
    Wien Med Wochenschr Suppl; 1989; 105():20-3. PubMed ID: 2694628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs for lipids.
    Treat Guidel Med Lett; 2014 Jan; 12(137):1-6; quiz 7-8. PubMed ID: 24419209
    [No Abstract]   [Full Text] [Related]  

  • 15. [HMG-CoA reductase inhibitors].
    Yamamoto A
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():578-86. PubMed ID: 11347135
    [No Abstract]   [Full Text] [Related]  

  • 16. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
    Lamendola C; Abbasi F; Chu JW; Hutchinson H; Cain V; Leary E; McLaughlin T; Stein E; Reaven G
    Am J Cardiol; 2005 Jan; 95(2):189-93. PubMed ID: 15642550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of lipid-lowering drugs.
    Med Lett Drugs Ther; 1998 Dec; 40(1042):117-22. PubMed ID: 9884672
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of fibrates in reducing coronary risk: a UK Consensus.
    UK HDL-C Consensus Group
    Curr Med Res Opin; 2004; 20(2):241-7. PubMed ID: 15006019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.